I really like this line from the quarterly, and it is something I had discussed with the company even before the RTO was complete...
'Botanix is also actively exploring opportunities to leverage its PermetrexTM skin delivery technology and growing team to rapidly advance other products into the clinic'.
Permetrex is something that will give our own products a competitive advantage, but this line suggests that it may well become a product that produces a revenue stream all of its own.
Licence arrangements with other companies, whose products are not in competition our pipeline, but also want to gain a competitive advantage.
An already well branded moisturiser, as an example, would gain greatly from including Permetrex and showing clinically that the cream will penetrate deeper into the skins layers than similar products.
Just thinking out loud, but the possibility must be there.
Milesy
BOT Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)